Pharmaceutical

BlossomHill secures $100m for cancer discovery programmes 

BlossomHill has secured $100m in a Series B financing round to advance its programmes targeting cancer and autoimmune diseases.

Mar 1, 2024 - 18:00
BlossomHill secures $100m for cancer discovery programmes 
BlossomHill has secured $100m in a Series B financing round to advance its programmes targeting cancer and autoimmune diseases.
Read the original article

Tags:

Previous Article

FDA lifts two-year clinical hold on CytoDyn’s HIV trial

Next Article

1910 Genetics and Microsoft partner to enhance pharmaceutical R&D

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Lilly’s EBGLYSS gains FDA approval for patients aged 12 and older

Lilly’s EBGLYSS gains FDA approval for patients aged 12...

Sep 16, 2024

With latest tranche, U.K. Biobank has genome sequences from 500,000 people available for research

With latest tranche, U.K. Biobank has genome sequences ...

Nov 29, 2023

Lawmakers call on FDA to issue stricter bone graft guidance

Lawmakers call on FDA to issue stricter bone graft guid...

Aug 31, 2023